Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

NCT03216070 is registered in ClinicalTrials.gov with Hospital Universitario Dr. Jose E. Gonzalez as lead sponsor.

NCT NCT03216070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03216070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Lead sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Phase
Phase 4
Overall status
Unknown status
Start date
April 1, 2016
Completion date
October 1, 2018
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukemia